Skip to Content

Amarantus Bioscience Holdings Inc - Stock Quote AMBS

Rating as of

Morningstar's Amarantus Bioscience Holdings Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - AMBS

Amarantus Bioscience Holdings Inc's Company Profile

Business Description

Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.

45 Wall Street, Suite 920
New York, NY, 10005
T +1 650 862-5391
Industry Biotechnology
Most Recent Earnings Mar 31, 2018
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 12